Compare ITGR & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | SLNO |
|---|---|---|
| Founded | 1970 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2000 | 2014 |
| Metric | ITGR | SLNO |
|---|---|---|
| Price | $69.60 | $52.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $92.86 | ★ $110.90 |
| AVG Volume (30 Days) | 623.1K | ★ 1.8M |
| Earning Date | 10-23-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $1,831,074,000.00 | $98,675,000.00 |
| Revenue This Year | $9.69 | N/A |
| Revenue Next Year | $0.48 | $155.86 |
| P/E Ratio | $28.71 | ★ N/A |
| Revenue Growth | ★ 9.54 | N/A |
| 52 Week Low | $62.00 | $41.50 |
| 52 Week High | $146.36 | $90.32 |
| Indicator | ITGR | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 49.80 |
| Support Level | $69.40 | $47.80 |
| Resistance Level | $71.49 | $53.10 |
| Average True Range (ATR) | 1.63 | 2.37 |
| MACD | 1.00 | 1.12 |
| Stochastic Oscillator | 46.59 | 87.75 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.